Figure 1. A novel diapeutic platform is based on phospholipid ether analogs.

Cellectar Biosciences has developed a phospholipid ether analog-based platform that is currently being investigated for diagnostic and therapeutic oncologic applications. ¹²⁴I-CLR1404 is currently under clinical investigation as a positron emission tomography (PET) tracer. ¹³¹I-CLR1404 is a therapeutic agent imaged by single photon emission computed tomography (SPECT) and CLR1502 is a near-infrared fluorescent labeled phospholipid ether analog being investigated for regional imaging applications.